| Literature DB >> 33111099 |
Emily M Thrash1, Katja Kleinsteuber1, Emma S Hathaway1, Matthew Nazzaro1, Eric Haas2, F Stephen Hodi1, Mariano Severgnini1.
Abstract
As mass cytometry (MC) is implemented in clinical settings, the need for robust, validated protocols that reduce batch effects between samples becomes increasingly important. Here, we present a streamlined MC workflow for high-throughput staining that generates reproducible data for up to 80 samples in a single experiment by combining reference sample spike-in and palladium-based mass-tag cell barcoding. Although labor intensive, this workflow decreases experimental variables and thus reduces technical error and mitigates batch effects.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33111099 PMCID: PMC7580234 DOI: 10.1016/j.xpro.2020.100055
Source DB: PubMed Journal: STAR Protoc ISSN: 2666-1667
Serial Dilution Preparation for Titrating Mass Cytometry Antibodies
| Tube # | μL of antibody | μL CyFACS | Final dilution |
|---|---|---|---|
| 1 | 4.8 μL | 55.2 | 1:25 |
| 2 | 30 μL from tube 1 | 30 | 1:50 |
| 3 | 30 μL from tube 2 | 30 | 1:100 |
| 4 | 30 μL from tube 3 | 30 | 1:200 |
| 5 | 30 μL from tube 4 | 30 | 1:400 |
| 6 | 30 μL from tube 5 | 30 | 1:800 |
| 7 | 30 μL from tube 6 | 30 | 1:1600 |
Figure 1Single Antibody Titration Data Generated by Mass Cytometry
(A) Ex vivo samples stained with 89Y_CD45 and stimulated samples stained with 141Pr_CD45 are separated in downstream manual gating analysis by plotting the two channels on a biaxial plot.
(B) CD69_144Nd single antibody titration data plotted as percent of total viable singlets.
Figure 2Using Surface Antibody Master Mix to Analyze Mass Cytometry Titration Data
CD11b titration data is used as an example for analyzing a marker with differential expression on cell types. This assists in placing the manually set gate on the viable cells. CD11b expression is expected to be positive on monocytes, with lower to no expression on B, T, and NKT cells. Increased background is observed as the antibody increases to 1:50 dilution in these cell types.
Surface Antibody Master Mix for Titrating Mass Cytometry Antibodies
| Surface Staining | ||||
|---|---|---|---|---|
| Marker | Metal | Clone | Dilution Factor | μL Added to MM |
| CD19 | 142Nd | HIB19 | 800 | 12.50 |
| CD3 | 143Nd | UCHT1 | 200 | 5.00 |
| CD4 | 145Nd | RPA-T4 | 200 | 5.00 |
| CD8a | 146Nd | RPA-T8 | 100 | 10.00 |
| CD11c | 147Sm | Bu15 | 1600 | 6.25 |
| CD14 | 162Dy | M5E2 | 400 | 2.50 |
| CD56 | 176Yb | NCAM16.2 | 800 | 12.50 |
| CD16 | 209Bi | 3G8 | 200 | 5.00 |
| CyFACS | 141.25 | |||
| Total MM Volume | 200.00 | |||
| Volume MM/sample (μL) | 10 | |||
| # of samples (+10%–20%) | 20 | |||
Adaptive Mass Cytometry Panel
| Marker | Metal | Clone | Vendor | Dilution Factor |
|---|---|---|---|---|
| CD19 | 142Nd | HIB19 | FDM | 800 |
| CD3 | 143Nd | UCHT1 | CIO | 100 |
| CD69 | 144Nd | FN50 | FDM | 200 |
| CD4 | 145Nd | RPA-T4 | FDM | 200 |
| CD8a | 146Nd | RPA-T8 | FDM | 100 |
| CD11c | 147Sm | Bu15 | FDM | 1600 |
| PD-L1 | 148Nd | 29E.2A3 | FDM | 100 |
| CD25 | 149Sm | 2A3 | FDM | 400 |
| OX40 | 150Nd | ACT35 | FDM | 50 |
| ICOS | 151Eu | C398.4A | FDM | 100 |
| CD95 | 152Sm | DX2 | FDM | 100 |
| CD45RA | 153Eu | HI100 | FDM | 50 |
| TIM-3 | 154Sm | F38-2E2 | FDM | 50 |
| PD-1 | 155Gd | EH12.2H7 | FDM | 100 |
| CXCR3 | 156Gd | G025H7 | FDM | 200 |
| 4-1BB | 158Gd | 4B4-1 | FDM | 100 |
| GITR | 159Tb | 108-17 | CIO | 100 |
| CD40L | 161Dy | 24-31 | CIO | 100 |
| CD14 | 162Dy | M5E2 | CIO | 200 |
| CRTH2 | 163Dy | BM16 | CIO | 50 |
| TIGIT | 164Dy | MBSA43 | CIO | 100 |
| LAG3 | 165Ho | 11C3C65 | CIO | 100 |
| CD28 | 166Er | CD28.8 | CIO | 100 |
| CCR7 | 167Er | G043H7 | FDM | 100 |
| CD127 | 168Er | A019D5 | FDM | 100 |
| CD33 | 169Tm | WM53 | FDM | 200 |
| CXCR5 | 171Yb | 51505 | FDM | 100 |
| PD-L2 | 172Yb | 24F.10C12 | FDM | 50 |
| CD123 | 174Yb | 6H6 | CIO | 100 |
| HLA-DR | 175Lu | L243 | CIO | 100 |
| CD56 | 176Yb | NCAM16.2 | FDM | 800 |
| CD16 | 209Bi | 3G8 | FDM | 200 |
| T-bet | 160Gd | 4B10 | FDM | 100 |
| CTLA-4 | 170Er | 14D3 | FDM | 200 |
| Granzyme B | 173Yb | GB11 | FDM | 800 |
Titrated antibodies of the adaptive immune response focused mass cytometry panel and dilution factors to make master mixes. Vendor listed as “CIO” refers to Center for Immuno-Oncology and indicates the antibody metal conjugation was performed in our lab.
Innate Mass Cytometry Panel
| Marker | Metal | Clone | Vendor | Dilution Factor |
|---|---|---|---|---|
| CD19 | 142Nd | HIB19 | FDM | 800 |
| CD3 | 143Nd | UCHT1 | CIO | 100 |
| CD15 | 144Nd | W6D3 | FDM | 100 |
| CD4 | 145Nd | RPA-T4 | FDM | 200 |
| CD8a | 146Nd | RPA-T8 | FDM | 100 |
| CD11c | 147Sm | Bu15 | FDM | 1600 |
| PD-L1 | 148Nd | 29E.2A3 | FDM | 100 |
| CD25 | 149Sm | 2A3 | FDM | 400 |
| CD86 | 150Nd | IT2.2 | FDM | 100 |
| ICOS | 151Eu | C398.4A | FDM | 100 |
| TCRgd | 152Sm | 11F2 | FDM | 50 |
| TCR Va7.2 | 153Eu | 3C10 | FDM | 100 |
| CD163 | 154Sm | GHI/61 | FDM | 50 |
| PD-1 | 155Gd | EH12.2H7 | FDM | 100 |
| NKG2D | 156Gd | 1D11 | CIO | 50 |
| CD33 | 158Gd | WM53 | FDM | 400 |
| NKp30 | 159Tb | Z25 | FDM | 100 |
| CD14 | 162Dy | M5E2 | CIO | 200 |
| Galectin-9 | 163Dy | 9M1-3 | FDM | 100 |
| TIGIT | 164Dy | MBSA43 | CIO | 100 |
| LAG3 | 165Ho | 11C3C65 | FDM | 100 |
| CD11b | 167Er | ICRF44 | FDM | 200 |
| CD68 | 171Yb | Y1/82A | FDM | 100 |
| PD-L2 | 172Yb | 24F.10C12 | FDM | 50 |
| CD123 | 174Yb | 6H6 | CIO | 100 |
| HLA-DR | 175Lu | L243 | CIO | 100 |
| CD56 | 176Yb | NCAM16.2 | FDM | 800 |
| CD16 | 209Bi | 3G8 | FDM | 200 |
| IFNy | 161Dy | B27 | CIO | 100 |
| IL-10 | 166Er | JES3-9D7 | FDM | 100 |
| Ki-67 | 168Er | B56 | FDM | 200 |
| CTLA-4 | 170Er | 14D3 | FDM | 200 |
| Granzyme B | 173Yb | GB11 | FDM | 800 |
Titrated antibodies of the innate immune response focused mass cytometry panel and dilution factors to make master mixes. Vendor listed as “CIO” refers to Center for Immuno-Oncology and indicates the antibody metal conjugation was performed in our lab.
Figure 3Comparing Storage Conditions of Surface Master Mix
Metal-conjugated antibody surface master mixes were prepared and stored at -80°C or 4°C for 16 h and healthy donor PBMCs were stained. Clones and metals are the same as used in the adaptive and innate panels, as listed in Tables 3 and 4.
Figure 4Plate Layout for Experimental Samples, Reference Samples, and CD45-Barcoded Reference Sample Spike-in
(A) Experimental samples (yellow wells) and reference samples (blue) are plated. Wells C10 and F10 contain the ex vivo reference sample, and wells C11 and F11 contain the stimulated reference sample. Keeping the two stimulated conditions separate guides downstream analysis (Figure 8).
(B) 1:1 mixed reference sample is “spike-in” to experimental sample (green wells). Each well now contains 2 million cells.
Figure 8Clean-up Gating with CD45 Barcoded Reference Sample Spike-in
A representative single fcs file is cleaned-up to identify viable single cells with reference sample and experimental sample separated by manually gating on the CD45 channels, 89Y and 141Pr.
Figure 520-Plex Palladium Isotope Barcode Strategy
A Barcode ID # (BC #) is assigned to each sample. Each BC # is positive for 3 of the six different Palladium isotopes (102, 104, 105, 106, 108, 110 Pd). In this schema, grayed out boxes indicate that this BC # is positive for that isotope. BC 1–18 are experimental samples with reference sample spike-in, and BC 19 and 20 are reserved for reference sample controls. Downstream gating of CD45 barcoding is shown on the right to indicate what samples are in which BC #.
Figure 7Tracking Increased Signal Drift Over Time during Long Sample Acquisitions
(A) 89Y_CD45 positive reference cells contribute to an increase in background signal when resuspended over the course of an acquisition of at least 2 h.
(B) Reference cells start as 141Pr_CD45 negative but contribute to increased background signal over time.
(C) 89Y_CD45 negative cells are shown to be 141Pr_CD45 positive cells. These analyses were performed on “live, intact, single cells”, thus the increase in background signal in the 141Pr channel cannot be attributed to cell doublets.
Figure 6Comparison of Injector Type on Signal Variability as Accessed by CD45_89Y Coefficient of Variable
Identical samples were acquired in replicate 100,000 events each for two different acquisition modes, Wide Bore (WB) and High Throughput (HT) injectors. The WB injector significantly decreased the variability of the CD45_89Y signal. p-value=0.0001, Welch Two Sample T-test.
Figure 9Tracking Cell Loss during Staining Protocol
Cell count changes over the course from post-thawing and plating, to how many events acquired, and after clean-up gating are shown for three independent healthy donor PBMC samples. Three healthy donor PBMC samples were stained for MC using our full protocol. We observed ≈ 75% cell loss (mean values: pre-stain = 2 million, events acquired = 136k, events per sample after clean-up gating (“viable, single cells”) = 77k).
Figure 10Independent Pd Barcode Ex Vivo and Stimulated Reference Samples Guides Gating
Ex vivo and Stimulated reference sample are run as independent samples of the barcoding strategy.
(A) Samples were analyzed using tSNE algorithm (viSNE maps created using cytobank.com) and show changes of major cell populations. Clusters indicate cell subsets and the major cell lineages are overlaid with colored dot plots. Each dot represents one cell.
(B) Manual gating (Flowjo) of ex vivo and stimulated samples guides where to place positive threshold gate for dynamic markers that are expected to increase with stimulation.
Figure 11Reference Sample Spike-In and Palladium Sample Barcoding Generates Reproducible Results
Stimulated and ex vivo healthy donor PBMC samples were stained with either the adaptive or innate MC panels. Two sets of palladium sample barcodes were used for each panel. Each barcode set included one independent sample of stimulated and ex vivo and the remaining 18 barcodes were replicate samples of 1:1 mixed stimulated and ex vivo samples.
(A) Manual gating was compared for cellular frequencies as percent of viable for 19 overlapping markers between the adaptive and innate panels for spike-in reference sample (n = 36 replicates spike-in reference samples, bar graph of mean with standard error of mean for error bars).
(B) Percent CV graph of data in shown in (A), dotted line at 5%.
(C) Comparison of 1:1 mixed stimulated and ex vivo samples as independent barcoded samples (n = 2/panel).
Figure 12Stimulation Conditions Are Tested to Detect Markers in Mass Cytometry Antibody Panels
Healthy donor PBMC samples were treated with various stimulation conditions at various timepoints: PMA + ionomycin, CD3/CD28 bead stimulation, or a combination of CD3/CD28 beads with PMA + ionomycin. Specific markers are highlighted here to represent the dynamic range of activating these markers. Top row: CD11c. Middle row: Lag-3. Bottom row: CD69.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Anti-Human CD45 (HI30)-Y89 | Fluidigm | Cat#3089003B |
| Anti-Human CD45 (HI30)-141Pr | Fluidigm | Cat#3141009B |
| Anti-Human CD19 (HIB19)-142Nd | Fluidigm | Cat#3142001B |
| Anti-Human CD69 (FN50)-144Nd | Fluidigm | Cat#3144018B |
| Anti-Human CD15/SSEA-1 (W6D3)-144Nd | Fluidigm | Cat#3144019B |
| Anti-Human CD4 (RPA-T4)-145Nd | Fluidigm | Cat#3145001B |
| Anti-Human CD8a (RPA-T8)-146Nd | Fluidigm | Cat#3146001B |
| Anti-Human CD11c (Bu15)-147Sm | Fluidigm | Cat#3147008B |
| Anti-Human CD274/PD-L1 (29E.2A3)-148Nd | Fluidigm | Cat#3148017B |
| Anti-Human CD25 (2A3)-149Sm | Fluidigm | Cat#3149010B |
| Anti-Human CD134/OX40 (ACT35)-150Nd | Fluidigm | Cat#3150023B |
| Anti-Human CD86/B7.2 (IT2.2)-150Nd | Fluidigm | Cat#3150020B |
| Anti-CD278/ICOS (C398.4A)-151Eu | Fluidigm | Cat#3151020B |
| Anti-Human CD95/Fas (DX2)-152Sm | Fluidigm | Cat#3152017B |
| Anti-Human TCRgd (11F2)-152Sm | Fluidigm | Cat#3152008B |
| Anti-Human CD45RA (HI100)-153Eu | Fluidigm | Cat#3153001B |
| Anti-Human TCR Va7.2 (3C10 )-153Eu | Fluidigm | Cat#3153024B |
| Anti-Human TIM-3 (F38-2E2)-154Sm | Fluidigm | Cat#3154010B |
| Anti-Human CD163 (GHI/61)-154Sm | Fluidigm | Cat#3154007B |
| Anti-Human CD279/PD-1 (EH12.2H7)-155Gd | Fluidigm | Cat#3155009B |
| Anti-Human CD183/CXCR3 (G025H7)-156Gd | Fluidigm | Cat#3156004B |
| Anti-Human CD137/4-1BB (4B4-1)-158Gd | Fluidigm | Cat#3158013B |
| Anti-Human CD33 (WM53)-158Gd | Fluidigm | Cat#3158001B |
| Anti-Human CD337/NKp30 (Z25)-159Tb | Fluidigm | Cat#3159017B |
| Anti-Human/Mouse Tbet (4B10)-160Gd | Fluidigm | Cat#3160010B |
| Anti-Human CD294/CRTH2 (BM16)-163Dy | Fluidigm | Cat#3163003B |
| Anti-Human Galectin-9 (9M1-3)-163Dy | Fluidigm | Cat#3163002B |
| Anti-Human CD223/LAG-3 (11C3C65)-165Ho | Fluidigm | Cat#3165037B |
| Anti-Human IL-10 (JES3-9D7)-166Er | Fluidigm | Cat#3166008B |
| Anti-Human CD197/CCR7 (G043H7)-167Er | Fluidigm | Cat#3167009A |
| Anti-Human CD11b/Mac-1 (ICRF44)-167Er | Fluidigm | Cat#3167011B |
| Anti-Human CD127/IL-7Ra (A019D5)-168Er | Fluidigm | Cat#3168017B |
| Anti-Ki-67 (B56)-168Er | Fluidigm | Cat#3168007B |
| Anti-Human CD33 (WM53)-169Tm | Fluidigm | Cat#3169010B |
| Anti-Human CD152/CTLA-4 (14D3)-170Er | Fluidigm | Cat#3170005B |
| Anti-Human CD185/CXCR5 (RF8B2)-171Yb | Fluidigm | Cat#3171014B |
| Anti-Human CD68 (Y1/82A)-171Yb | Fluidigm | Cat#3171011B |
| Anti-Human CD273/PDL2 (24F.10C12)-172Yb | Fluidigm | Cat#3172014B |
| Anti-Human/Mouse Granzyme B (GB11)-173Yb | Fluidigm | Cat#3173006B |
| Anti-Human CD56 (NCAM16.2)-176Yb | Fluidigm | Cat#3176008B |
| Anti-Human CD16 (3G8)-209Bi | Fluidigm | Cat#3209002B |
| LEAF™ Purified anti-human CD154 Antibody (CD40L) | BioLegend | Cat#310812; Clone 24-31 |
| Purified anti-human CD123 | BioLegend | Cat#306002; Clone 6H6 |
| Purified anti-human CD28 (Maxpar® Ready) | BioLegend | Cat#302937; Clone CD28.2 |
| Purified anti-human CD3 (Maxpar® Ready) | BioLegend | Cat#300443; Clone UCHT1 |
| Purified anti-human CD357 (GITR) | BioLegend | Cat#371202; Clone 108-17 |
| Ultra-LEAF™ Purified anti-human CD14 | BioLegend | Cat#301862; Clone M5E2 |
| Ultra-LEAF™ Purified anti-human CD314 (NKG2D) | BioLegend | Cat#320814; Clone 1D11 |
| Ultra-LEAF™ Purified anti-human HLA-DR | BioLegend | Cat#307648; Clone L243 |
| Ultra-LEAF™ Purified anti-human IFN-γ Antibody | BioLegend | Cat#506512; Clone B27 |
| TIGIT Monoclonal Antibody (MBSA43), Functional Grade | eBioscience | Cat#16-9500-82 |
| Leukoreduction apheresis collar | Brigham and Women’s Hospital | N/A |
| BD Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit (Fixation/Permeabilization solution and BD Perm/Wash™ Buffer) | BD Biosciences | Cat#554714 |
| Antibody Stabilizer (PBS) | Candor Bioscience | Cat#131050 |
| Dimethyl Sulfoxide, Fisher BioReagents™ (DMSO) | Fisher Scientific | Cat# BP231-100 |
| Cell-ID™ Intercalator-Ir—125 μM | Fluidigm | Cat#201192A |
| Cell-ID™ Intercalator-Rh—500 μM | Fluidigm | Cat#201103A |
| EQ™ Four Element Calibration Beads | Fluidigm | Cat#201078 |
| Maxpar® Cell Acquisition Solution | Fluidigm | Cat#201240 |
| MaxPar® Cell Staining Buffer | Fluidigm | Cat#201068 |
| Antibiotic-Antimycotic (100×) | Gibco | Cat#15240062 |
| Dynabeads™ Human T-Activator CD3/CD28 | Gibco | Cat#11131D |
| Fetal Bovine Serum, certified, heat inactivated (FBS) | Gibco | Cat#10082147 |
| PBS, pH 7.4 | Gibco | Cat#10010023 |
| RPMI 1640 Medium | Gibco | Cat#11875093 |
| UltraPure™ DNase/RNase-Free Distilled Water | Invitrogen | Cat#10977015 |
| FcR Blocking Reagent, Human | Miltenyi Biotec | Cat#130-059-901 |
| AOPI Staining Solution in PBS | Nexcelom Biosciences | Cat#CS2-01060-5ML |
| Bovine Serum Albumin (BSA), 30% in 0.85% NaCl | Sigma-Aldrich | Cat#A7284 |
| Sodium azide, 10% (w/v) solution in DI water | Teknova | Cat#S0209 |
| Bond-Breaker™ TCEP Solution, Neutral pH | Thermo Scientific | Cat#77720 |
| Pierce™ 16% Formaldehyde (w/v), Methanol-free | Thermo Scientific | Cat#28906 |
| Maxpar® X8 Antibody Labeling Kit, 143Nd | Fluidigm | Cat#201143A |
| Maxpar® X8 Antibody Labeling Kit, 156Gd | Fluidigm | Cat#201156A |
| Maxpar® X8 Antibody Labeling Kit, 159Tb | Fluidigm | Cat#201159A |
| Maxpar® X8 Antibody Labeling Kit, 161Dy | Fluidigm | Cat#201161A |
| Maxpar® X8 Antibody Labeling Kit, 162Dy | Fluidigm | Cat#201162A |
| Maxpar® X8 Antibody Labeling Kit, 164Dy | Fluidigm | Cat#201164A |
| Maxpar® X8 Antibody Labeling Kit, 166Er | Fluidigm | Cat#201166A |
| Maxpar® X8 Antibody Labeling Kit, 174Yb | Fluidigm | Cat#201174A |
| Maxpar® X8 Antibody Labeling Kit, 175Lu | Fluidigm | Cat#201175A |
| Cell-ID™ 20-Plex Pd Barcoding Kit | Fluidigm | Cat#201060 |
| FlowJo | Becton, Dickinson & Company | |
| Cytobank | Cytobank Inc. | |
| CyTOF Software Version 6.7.1014 | Fluidigm | |
| 1.7 mL Polypropylene Microcentrifuge Tubes | Corning Inc. | Cat#MCT-175-C-S |
| 150 cm2 Cell Culture Flask, treated | Corning Inc. | Cat#3291 |
| 15 mL Polypropylene Centrifuge Tubes | Corning Inc. | Cat#430052 |
| 50 mL Polypropylene Centrifuge Tubes | Corning Inc. | Cat#430829 |
| 96-well V-bottom plate, untreated | Corning Inc. | Cat#3896 |
| Falcon® 5 mL Round Bottom Polypropylene Tubes (FACS Tubes) | Corning Inc. | Cat#352063 |
| Falcon® 5 mL Round Bottom Polystyrene Test Tube, with Cell Strainer Snap Cap 35 μm Cell Strainer Snap Cap | Corning Inc. | Cat#352235 |
| Amicon Ultra-0.5 Centrifugal Filter Unit, 3 kDa | Millipore | Cat#UFC500396 |
| Amicon Ultra-0.5 Centrifugal Filter Unit, 30 kDa | Millipore | Cat#UFC503024 |
| Ultrafree-MC Centrifugal Filter, 0.1 μm | Millipore | Cat#UFC30VV00 |
| ThermoFisher Scientific™ Sorvall™ Legend™ XTR Centrifuge TX-1000 rotor | ThermoFisher Scientific™ | Cat#75004521 |
| ThermoFisher Scientific Sorvall™ Legend™ Micro 21R | ThermoFisher Scientific™ | Cat#75002446 |
| FisherBrand Mini-Centrifuge | ThermoFisher Scientific™ | Cat#12-006-901 |
| Fisher Scientific Digital Vortex Mixer | ThermoFisher Scientific™ | Cat#0215370 |
| ThermoFisher Scientific Precision™ Water Bath | ThermoFisher Scientific™ | Cat#TSCIR19 |
| ThermoFisher Scientific Forma™ Steri-Cycle™ CO2 Incubator | ThermoFisher Scientific™ | Model 370 |
| Nexcelom Biosciences Cellometer Auto 2000 Cell Counter | Nexcelom Biosciences | Auto 2000 |
| SD100 Slides | Nexcelom Biosciences | CHT4-SD100-002 |
| Fluidigm Helios™ Mass Cytometer | Fluidigm | PN#101-0723 |
| WB Injector for Helios™ Mass Cytometer | Fluidigm | Cat#107950 |
Supplemented RPMI
| Reagent | Volume (mL) | Final Concentration |
|---|---|---|
| RPMI 1640 Medium | 500 | n/a |
| FBS | 50 | 10% |
| 100× antibiotic-antimycotic | 5 | 1× |
CyFACS
| Reagent | Volume (mL) | Final Concentration |
|---|---|---|
| PBS | 500 | n/a |
| 30% BSA | 8.3 | 0.5% |
| 5% sodium azide | 2 | 0.02% |
Freezing Media
| Reagent | Volume (mL) | Final Concentration |
|---|---|---|
| FBS | 25 | 85% |
| DMSO | 4.4 | 15% |